Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands.

Autor: Vestjens SMT; Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands., Wagenvoort GHJ; Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands. Electronic address: wagenvoort@gmail.com., Grutters JC; Interstitial Lung Diseases Centre of Excellence, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands; Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands., Meek B; Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands., Aldenkamp AF; Department of Respiratory Medicine, Catharina Hospital, Eindhoven, The Netherlands., Vlaminckx BJM; Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands., Bos WJW; Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands., Rijkers GT; Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands; Department of Sciences, University College Roosevelt, Middelburg, The Netherlands., van de Garde EMW; Department of Clinical Pharmacy, St. Antonius Hospital, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2017 Jul 24; Vol. 35 (33), pp. 4112-4118. Date of Electronic Publication: 2017 Jun 28.
DOI: 10.1016/j.vaccine.2017.06.049
Abstrakt: Background: In 2006 a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in the immunisation programme for infants in The Netherlands and replaced by PCV10 in 2011. Limited data exist about the impact of PCV on the aetiology of CAP as a whole. The aim of the present study is to describe the overall changes in microbial aetiology, pneumococcal burden (including non-bacteraemic pneumococcal pneumonia) and its serotypes in adult community-acquired pneumonia (CAP) after the introduction of these PCVs.
Methods: Hospitalised adult CAP patients who participated in three consecutive trials were studied (2004-2006 (n=201), 2007-2009 (n=304) and 2012-2016 (n=300) and considered as pre-PCV7, PCV7 and PCV10 period). Extensive conventional microbiological testing was applied for all patients. In addition, patients with a serotype-specific pneumococcal antibody response were diagnosed with pneumococcal CAP. Changes in proportions of causative pathogens and distributions of pneumococcal serotypes were calculated.
Results: The proportion of pneumococcal CAP decreased from 37% (n=74/201) to 26% (n=77/300) comparing the pre-PCV7 period with the PCV10 period (p=0.01). For other pathogens, including Legionella spp., Mycoplasma pneumoniae, S. aureus, H. influenzae, and respiratory viruses, no sustained shifts were observed in their relative contribution to the aetiology of CAP. Within the pneumococcal CAP patients, we observed a decrease in PCV7 and an increase in non-PCV10 serotype disease. PCV10-extra type disease did not decrease significantly comparing the PCV10 period with the pre-PCV7 and PCV7 period, respectively. Notably, PCV7 type disease decreased both in bacteraemic and non-bacteraemic patients.
Conclusions: Our findings confirm that PCV introduction in infants impact the microbial aetiology of adult CAP and suggest herd effects in adults with CAP after introduction of PCVs in children.
(Copyright © 2017 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: